Intellia Therapeutics
Agent42Agent Readiness: 42/100. Above median. Measured by StartupHub.ai. Median 41.Trust95Data Trust: 95/100. Top 25%. Measured by StartupHub.ai. Median 61.A clinical-stage genome editing company developing novel therapies using CRISPR/Cas9 technology for severe diseases.
About
Intellia Therapeutics is a leading clinical-stage genome editing company focused on developing curative therapeutics using its proprietary CRISPR/Cas9 technology. The company aims to precisely edit genes within the body to treat a range of severe diseases, including genetic disorders and cancer, offering potentially transformative treatments for patients.
Listed competitors
A clinical-stage biotechnology company developing transformative genome editing medicines for serious diseases.
A biotechnology company developing precision genetic medicines through base editing technology to treat a broad range of diseases.
Biotechnology company developing transformative gene-based medicines using CRISPR/Cas9 gene editing technology.
Also in this space
Develops advanced gene editing and cell therapy solutions for rare genetic diseases.
Shares Biotech, MedTech
Developing genetic medicines and cell therapies for severe diseases using proprietary CRISPR OMNI technology.
Shares CRISPR, Biotech
Developing gene editing therapies to lower cholesterol.
Shares Gene Therapy, Biotech
Scalable, one-time curative in-vivo gene editing therapies.
Shares Gene Therapy, Biotech
Developing gene editing therapies for rare genetic diseases.
Shares Biotech, MedTech
Biotechnology company leveraging ultracompact CRISPR systems for gene editing therapies and diagnostics.
Shares Drug Discovery, Genomics
Key facts
- Website
- intelliatx.com
- Headquarters
- Cambridge, United States
- Founded
- 2014
- Total funding
- $310M (Series C)
- Business model
- B2B
Funding rounds
| Date | Round | Amount | Lead investors |
|---|---|---|---|
| 1 Aug 2016 | Series C | $225M | |
| 1 Sept 2015 | Series B | $70M | OrbiMed |
| 18 Nov 2014 | Series A | $15M | Atlas Venture, Novartis Venture Fund (NVF) |
Tech stack
Detected on intelliatx.com, last scanned 30 Aug 2026. Run your own scan
- Frontend
- jQuery
- Analytics
- Google Analytics 4, Hotjar, Fathom
- SEO
- Yoast SEO
- CMS / Builders
- WordPress
- CDN
- Cloudflare
- Email provider
- Mimecast
- Cookie consent
- Cookiebot
- Video / media
- Vimeo
- Accessibility
- UserWay
Intellia Therapeutics scores 62. Does yours?
That is its Ahrefs DR: the backlink strength of a domain, on the Ahrefs 0 to 100 scale. Paste your website and you get yours in about a minute.
Frequently asked
Is Intellia Therapeutics trustworthy and reputable?
StartupHub's Data Trust & Reputation score for Intellia Therapeutics is 95 out of 100, a trusted rating, based on site security posture, privacy practices, malware and phishing checks, and public reputation signals.
How much funding has Intellia Therapeutics raised?
Intellia Therapeutics has raised a total of $310M in funding. The most recent round on record is Series C.
Public record
SEC filings, insider activity, nonprofit links and pay benchmarks for Intellia Therapeutics
